In this case study, Merck, a $60B+ global biopharmaceutical company, partnered with Mayo Clinic, the world’s top-ranked hospital system, to solve a fundamental tension in AI-enabled drug discovery: pharmaceutical companies need high-quality clinical data to train AI models, but patient privacy regulations and data security concerns prevent hospitals from sharing data. Through Mayo Clinic Platform_Orchestrate — a secure clinical and genomic data environment — Merck’s AI models run on Mayo’s data within Mayo’s secure environment, creating a model for pharma-hospital AI collaboration without data transfer. We evaluated this partnership to help your team structure similarly data-driven alliances.
1. Executive Summary
In February 2026, Merck and Mayo Clinic announced an R&D agreement applying AI, advanced analytics, and multimodal clinical data to drug discovery. Merck gains access to Mayo Clinic Platform_Orchestrate — a secure clinical and genomic data environment — to validate AI models and accelerate target identification across gastroenterology, dermatology, and neurology. The partnership is Mayo Clinic’s first strategic collaboration of this scale with a global biopharma company, and the Platform_Orchestrate model — AI travels to the data, not the reverse — creates a replicable framework for pharma-hospital AI partnerships.
- Subject: Merck ($60B+ pharma company, expanding AI-enabled discovery) and Mayo Clinic (world’s top-ranked hospital, Platform architecture for multimodal clinical data)
- Problem: Pharma companies need high-quality clinical data to train AI models, but patient privacy regulations and data security concerns prevent data sharing
- Solution: Platform_Orchestrate model — AI travels to the data, not the reverse. Merck’s models run within Mayo’s secure environment.
- Result: Mayo Clinic’s first large-scale pharma collaboration; three therapeutic areas defined; Platform architecture validated for external AI access
2. The Challenge
Patient privacy regulations including HIPAA in the U.S. and GDPR in Europe make it nearly impossible for hospitals to share clinical data with pharmaceutical companies. Most pharma-hospital data partnerships fail because they require data transfer, creating privacy, regulatory, and competitive risks that neither side can fully accept. Meanwhile, academic medical centers like Mayo Clinic hold 100+ years of curated clinical data that could transform AI-enabled drug discovery, but they lack the AI infrastructure to fully leverage this data.
- Privacy barrier: Patient privacy regulations make it nearly impossible for hospitals to share clinical data with pharma companies.
- Data transfer risk: Most pharma-hospital data partnerships fail because data must be transferred, creating privacy and competitive risks.
- AI infrastructure gap: Academic medical centers lack the AI infrastructure to exploit their own clinical data fully.
Both sides recognized the opportunity: Merck had the AI models and drug discovery expertise, Mayo Clinic had the clinical data and Platform architecture. The challenge was designing a structure that gave Merck access to Mayo’s data without ever transferring it.
3. The Strategy
Rather than transferring patient data to Merck — which would create insurmountable privacy and regulatory hurdles — Mayo Clinic’s Platform_Orchestrate model brings Merck’s AI models to Mayo’s data within Mayo’s secure environment. This structural innovation — AI travels to the data, not the reverse — solves the fundamental tension in healthcare data partnerships. The agreement covers three focused therapeutic areas and provides direct access to Mayo’s clinical and scientific expertise, not just data.
- Platform_Orchestrate: Merck’s AI models run on Mayo’s data within Mayo’s secure environment — data never leaves Mayo. This eliminates privacy, regulatory, and competitive concerns.
- Multimodal data integration: Lab results, imaging, clinical notes, molecular data integrated in a single platform — providing a richer dataset than any single data type could offer.
- Focused therapeutic areas: Three initial areas (IBD, atopic dermatitis, MS) rather than broad data access — reducing complexity and generating faster results.
The partnership leverages Mayo Clinic’s existing Platform architecture — already built and commercialized before seeking pharma partners — making the collaboration possible without a massive upfront IT investment. Mayo Clinic’s President and CEO described the structure as combining “de-identified data, clinical expertise and Platform technology with Merck’s world-class R&D capabilities.”
4. The Results
The partnership, announced in February 2026, represents Mayo Clinic’s first strategic collaboration of this scale with a global biopharma company. Merck gains access to 100+ years of curated clinical data without data transfer or privacy liability. The Platform_Orchestrate model is now validated for pharmaceutical AI partnerships with defined expansion pathways.
- First-of-scale collaboration: Mayo Clinic’s first strategic collaboration of this scale with a global biopharma company — signaling a new partnership model.
- Secure data access: Merck gains access to 100+ years of curated clinical data without data transfer or privacy liability.
- Validated platform model: Platform_Orchestrate model validated for pharmaceutical AI partnerships with defined expansion pathways beyond the initial three therapeutic areas.
Long-term output — validated AI models for target identification, biomarker discovery, and clinical decision support — is expected to materialize over 3-5 years. The partnership builds on Merck’s broader AI investments in computational biology, AI foundation models, and real-world data, suggesting the collaboration will accelerate existing Merck programs rather than start from scratch.
5. The Melan Approach
Melan advises structuring partnerships like this one when the data asset is the primary partnership driver — the Platform_Orchestrate model works best when an academic medical center has existing secure data infrastructure and a pharma company has AI models that can travel to the data.
- Governance model: Joint governance through Merck AI leadership and Mayo Clinic Platform leadership. Melan would recommend establishing a formal joint steering committee for data access expansion and therapeutic area prioritization with defined decision rights.
- Risk allocation: Data asset valuation is complex — proper valuation of data access is difficult and could lead to under-compensation. Melan recommends allocating budget for independent data valuation and exclusivity negotiation to ensure both sides are fairly compensated.
- Shared goal: Accelerate AI-enabled drug discovery through secure clinical data access while establishing a replicable platform model for pharma-hospital AI collaboration. Melan would add mid-term governance review clauses to adjust therapeutic focus areas as AI models and data capabilities evolve.
This Platform_Orchestrate model is replicable for any academic medical center with secure data platform infrastructure and any pharma company with AI capabilities. The critical success factor is existing platform infrastructure — Mayo Clinic had already built and commercialized its Platform architecture before seeking pharma partners — making the collaboration possible without a massive upfront IT investment.
Ready to build a pharma-hospital AI data partnership?
Melan helps pharmaceutical companies and academic medical centers structure data platform partnerships with secure AI access, fair data valuation, and defined governance frameworks.
